![Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer](https://www.spandidos-publications.com/article_images/ijo/46/3/IJO-46-03-1025-g04.jpg)
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
![Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2b58824f-af1b-4d6f-bd2e-b5ba49d84e73/gr1.jpg)
Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine
![Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract] Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]](https://www.ijbs.com/v16/p2595/toc.jpg)
Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation [Abstract]
![Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6d8e24ed-aece-4976-8af5-b185e5b710fc/gr1_lrg.jpg)
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
![Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression | BMC Cancer | Full Text Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression | BMC Cancer | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-018-5078-y/MediaObjects/12885_2018_5078_Fig3_HTML.png)
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression | BMC Cancer | Full Text
![Crizotinib inhibits c-MET activation and shows in-vitro efficacy in CRC... | Download Scientific Diagram Crizotinib inhibits c-MET activation and shows in-vitro efficacy in CRC... | Download Scientific Diagram](https://www.researchgate.net/profile/Elena-Shagisultanova-2/publication/319559624/figure/fig4/AS:668669147373569@1536434556060/Crizotinib-inhibits-c-MET-activation-and-shows-in-vitro-efficacy-in-CRC-cell-lines-A.png)
Crizotinib inhibits c-MET activation and shows in-vitro efficacy in CRC... | Download Scientific Diagram
![Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer](https://www.spandidos-publications.com/article_images/ijo/46/3/IJO-46-03-1025-g00.jpg)
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
![Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2088033291/2074826410/gr1.jpg)
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
![Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/dba34d99-aa92-4116-b63f-56e8922f3e71/gr3_lrg.jpg)
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
![Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/4478dc7e-52d0-443d-a609-959490c0590d/gr1.jpg)
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
![Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication - Lung Cancer Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/2adf6499-8769-4ed7-af8f-0105f048dc34/gr4.jpg)
Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication - Lung Cancer
![ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer: Cell Reports ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer: Cell Reports](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2020605120/2040313900/fx1.jpg)
ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer: Cell Reports
![Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation - Clinical Lung Cancer Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation - Clinical Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2035385799/2050854689/gr1.jpg)
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation - Clinical Lung Cancer
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
![Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4a3b1249-6039-43e2-b043-6344633ae667/gr1_lrg.jpg)
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology
PLOS ONE: Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
![Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-019-0716-8/MediaObjects/41591_2019_716_Fig1_HTML.png)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
![Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | Semantic Scholar Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4bc2bb0c54ee017cdd6ccf5a3a4e079f1774ed56/3-Figure1-1.png)
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | Semantic Scholar
![Downregulation of MET in H1993 cells, effects of crizotinib on EGFR... | Download Scientific Diagram Downregulation of MET in H1993 cells, effects of crizotinib on EGFR... | Download Scientific Diagram](https://www.researchgate.net/profile/Francesca-Iommelli/publication/264164554/figure/fig2/AS:281136656863256@1444039610956/Downregulation-of-MET-in-H1993-cells-effects-of-crizotinib-on-EGFR-signaling-in-H1993.png)
Downregulation of MET in H1993 cells, effects of crizotinib on EGFR... | Download Scientific Diagram
![Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology](https://memoinoncology.com/wp-content/uploads/2020/02/82498.gif)
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
![Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Future Oncology Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon.13.179/asset/images/medium/figure2.gif)
Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Future Oncology
![CRZ in MET-Rearranged NSCLC - Lung Cancer - 2016 American Society of Clinical Oncology Annual Meeting - Oncology - Clinical Care Options CRZ in MET-Rearranged NSCLC - Lung Cancer - 2016 American Society of Clinical Oncology Annual Meeting - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/clin-onc-june-2016/cco_clin_onc_2016_lung_108_drilon_thumb.png?rev=f03598457e1d45a0902d270abd05b55d&h=200&as=1&hash=BB3986E93C34E7764AB3170A7B1A5EAD869E5F70)